These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2454354)

  • 1. Efficacy and safety of carvedilol in the treatment of hypertension.
    Schnurr E; Widmann L; Glocke M
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S101-7. PubMed ID: 2454354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
    Ogihara T; Ikeda M; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S108-12. PubMed ID: 2454355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of carvedilol in severe hypertension.
    Ogihara T; Yoshinaga K; Kamahara Y; Ikeda M; Goto Y; Arakawa K; Iimura I; Ishii M; Kokubu T; Takeda T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S69-72. PubMed ID: 1721983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
    Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
    Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension.
    Langdon CG; Baxter GA; Young PH
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S51-6. PubMed ID: 1721980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian antihypertensive profile of carvedilol (BM 14190).
    Meyer-Sabellek W; Schulte KL; Distler A; Gotzen R
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S119-23. PubMed ID: 2454357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release carvedilol in the treatment of essential hypertension.
    Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
    Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide.
    van der Does R; Widmann L; Uberbacher HJ; Hörrmann M; Machwirth M; Stienen U
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S147-52. PubMed ID: 1974506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
    Ollivier JP; Durier P; Bussiere JL; Gayet JL
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S164-6. PubMed ID: 1974509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-effect relationship of carvedilol in essential hypertension. An open study.
    Ogihara T; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T; Arakawa K
    Drugs; 1988; 36 Suppl 6():75-81. PubMed ID: 2908305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
    Ruilope LM
    Am J Hypertens; 1994 Feb; 7(2):129-36. PubMed ID: 7910028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resting and postexercise hemodynamic effects of carvedilol, a beta-adrenergic blocker and precapillary vasodilator in hypertensive patients.
    Leonetti G; Sampieri L; Cuspidi C; Boselli L; Terzoli L; Rupoli L; Zanchetti A
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S94-6. PubMed ID: 2454377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study.
    McPhillips JJ; Schwemer GT; Scott DI; Zinny M; Patterson D
    Drugs; 1988; 36 Suppl 6():82-91. PubMed ID: 2908306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with carvedilol.
    Moser M
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S16-20. PubMed ID: 8098064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics.
    Dupont AG; Schoors DF; Venuti RP
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S153-7. PubMed ID: 1974507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension.
    Miki S; Masumura H; Kaifu Y; Yuasa S
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term carvedilol therapy on renal function in essential hypertension.
    Tomita K; Marumo F
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S97-101. PubMed ID: 1378158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-pressure-lowering effect of carvedilol vs nitrendipine in geriatric hypertensives.
    Krönig B; Widmann L; Staiger C; Machwirth M; Stienen U; Hennig M; Müller-Beckmann B
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S167-70. PubMed ID: 1974510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rate with respect to the blood pressure-lowering effect of the vasodilating and beta-blocking agent carvedilol.
    Rittinghausen R
    Drugs; 1988; 36 Suppl 6():92-101. PubMed ID: 2908307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.